Internal Medicine, Rheumatology · Tulsa, OK
NPI
1154382711
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
4812 S 109th East Ave, Ste. 200
Tulsa, OK, 74146
Phone (918) 236-4567
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
202,000 services
Medicare patients, 2024
518
Average age 73
Drug cost, 2024
$5.5M
5,624 prescriptions
Company payments, 2025
$4,835
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William Surbeck was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 90,800 times for 23 patients. In total William Surbeck billed 202,000 services in 48 codes, and Medicare paid $1.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-09-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 90,800 | 23 | $3.61 | $328K |
| J3262 Injection, tocilizumab, 1 mg | Office | 55,005 | 13 | $4.71 | $259K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 21,725 | 26 | $9.05 | $197K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 14,175 | 22 | $33.36 | $473K |
| J9312 Injection, rituximab, 10 mg | Office | 5,350 | 20 | $59.35 | $318K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,660 | 15 | $24.93 | $116K |
| J0897 Injection, denosumab, 1 mg | Office | 3,300 | 31 | $19.67 | $65K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,680 | 11 | $0.09 | $159 |
| 99214 Office E&M - Established | Office | 1,044 | 460 | $79.34 | $83K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,038 | 21 | $0.22 | $228 |
| 96372 Injection Administration | Office | 529 | 67 | $9.40 | $4,971 |
| 96365 Intravenous Infusion, Hydration | Office | 321 | 47 | $40.73 | $13K |
| 96413 Chemotherapy Administration | Office | 272 | 53 | $79.95 | $22K |
| 96415 Chemotherapy Administration | Office | 243 | 35 | $17.90 | $4,350 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 93 | 19 | $0.59 | $54.54 |
By year: 2022 $2.1M for 188,313 services; 2023 $2.1M for 204,574 services; 2024 $1.9M for 202,000 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 20 | 15 | $2.24 | $44.87 |
Medicare prescription drug claims, 2024
In 2024, the drug William Surbeck prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 1,021 prescriptions and refills. In total William Surbeck wrote 5,624 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 1,021 | 1,942 | 212 | $32K |
| Hydroxychloroquine Sulfate Generic | 1,014 | 2,087 | 221 | $40K |
| Prednisone Generic | 606 | 858 | 115 | $3,779 |
| Gabapentin Generic | 246 | 406 | 48 | $4,042 |
| Leflunomide Generic | 244 | 464 | 60 | $17K |
| Tramadol Hcl Generic | 228 | 230 | 34 | $1,927 |
| Humira(Cf) Pen Adalimumab | 164 | 167 | 18 | $1.4M |
| Enbrel Sureclick Etanercept | 148 | 166 | 16 | $1.3M |
| Allopurinol Generic | 116 | 269 | 26 | $1,447 |
| Folic Acid Generic | 111 | 280 | 27 | $1,418 |
| Celecoxib Generic | 105 | 187 | 21 | $2,638 |
| Leucovorin Calcium Generic | 102 | 174 | 20 | $824 |
| Meloxicam Generic | 88 | 193 | 22 | $673 |
| Sulfasalazine Generic | 76 | 153 | 17 | $2,088 |
| Rinvoq Upadacitinib | 71 | 76 | 11 | $474K |
Brand drugs: - claims; generic drugs: 4,757 claims; opioid claims: 331.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William Surbeck $4,835 ($4,835 in general payments such as food, travel and fees) from 14 companies. The largest payer was Janssen Biotech, Inc. with $2,650.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 10 | $2,650 |
| Amgen Inc. AMGN | 31 | $480 |
| Abbvie Inc. ABBV | 21 | $437 |
| UCB, Inc. UCB.BR | 16 | $385 |
| GlaxoSmithKline, LLC. GSK | 9 | $166 |
| Pfizer Inc. PFE | 8 | $151 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $146 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $141 |
| Fresenius Kabi USA, LLC | 4 | $80.58 |
| Genentech USA, Inc. ROG.SW | 4 | $63.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.